C M Florkowski

Summary

Country: New Zealand

Publications

  1. ncbi Two cases of adrenal suppression following a Chinese herbal remedy: a cause for concern?
    C M Florkowski
    Canterbury Health Laboratories, Christchurch Hospital
    N Z Med J 115:223-4. 2002
  2. ncbi Thyroid hormone resistance: the role of mutational analysis
    C M Florkowski
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Intern Med J 36:738-41. 2006
  3. ncbi Haemoglobin Marseille-Long Island and interpretation of HbA1c: which HbA1c result is the "right answer"?
    C M Florkowski
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Postgrad Med J 79:174-5. 2003
  4. ncbi Cause-specific and total mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population: a 15-year follow-up study
    C M Florkowski
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabet Med 20:191-7. 2003
  5. ncbi Comparison of blood glucose meters in a New Zealand diabetes centre
    Christopher Florkowski
    Diabetes Centre, Christchurch Hospital, Christchurch, New Zealand
    Ann Clin Biochem 46:302-5. 2009
  6. ncbi Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of Type 1 diabetic subjects in Canterbury, New Zealand
    C M Florkowski
    Lipid and Diabetes Research Group, Hagley Building, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Res Clin Pract 52:125-31. 2001
  7. ncbi Clinical and biochemical outcomes of type 2 diabetes mellitus in Canterbury, New Zealand: a 6-year cohort study
    C M Florkowski
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabetes Res Clin Pract 40:167-73. 1998
  8. ncbi Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study
    C M Florkowski
    Lipid and Diabetes Research Group, Hagley Building, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Res Clin Pract 53:113-20. 2001
  9. ncbi What is the best predictor of the atherogenic LDL subclass phenotype 'pattern B' in patients with type 2 diabetes mellitus?
    R I King
    Clinical Biochemistry, Canterbury Health Laboratories, Christchurch, New Zealand
    Ann Clin Biochem 48:166-9. 2011
  10. ncbi A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria
    B I Shand
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabetes Nutr Metab 14:201-6. 2001

Collaborators

Detail Information

Publications23

  1. ncbi Two cases of adrenal suppression following a Chinese herbal remedy: a cause for concern?
    C M Florkowski
    Canterbury Health Laboratories, Christchurch Hospital
    N Z Med J 115:223-4. 2002
  2. ncbi Thyroid hormone resistance: the role of mutational analysis
    C M Florkowski
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Intern Med J 36:738-41. 2006
    ..Mutational analysis also enables family screening and may help to avoid potential misdiagnosis and inappropriate treatment...
  3. ncbi Haemoglobin Marseille-Long Island and interpretation of HbA1c: which HbA1c result is the "right answer"?
    C M Florkowski
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Postgrad Med J 79:174-5. 2003
    ..2%) compared with the non-diabetic range of less than 6.4%. Mass spectral studies confirmed the presence a haemoglobin variant, haemoglobin Marseille-Long Island which had confounded interpretation by all methods...
  4. ncbi Cause-specific and total mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population: a 15-year follow-up study
    C M Florkowski
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabet Med 20:191-7. 2003
    ..To establish all-cause and cause-specific death rates, and risk factors for mortality in insulin-treated diabetic individuals living in the province of Canterbury, New Zealand...
  5. ncbi Comparison of blood glucose meters in a New Zealand diabetes centre
    Christopher Florkowski
    Diabetes Centre, Christchurch Hospital, Christchurch, New Zealand
    Ann Clin Biochem 46:302-5. 2009
    ..To assess the accuracy and precision of the Roche Performa and Medisense Optium Xceed (5 and 10 s reading) blood glucose meters...
  6. ncbi Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of Type 1 diabetic subjects in Canterbury, New Zealand
    C M Florkowski
    Lipid and Diabetes Research Group, Hagley Building, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Res Clin Pract 52:125-31. 2001
    ..Peri-pubertal age at diagnosis (10-14 years) did not influence the time to onset of retinopathy over and above that attributed to duration of diabetes and glycaemic control...
  7. ncbi Clinical and biochemical outcomes of type 2 diabetes mellitus in Canterbury, New Zealand: a 6-year cohort study
    C M Florkowski
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabetes Res Clin Pract 40:167-73. 1998
    ....
  8. ncbi Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study
    C M Florkowski
    Lipid and Diabetes Research Group, Hagley Building, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Res Clin Pract 53:113-20. 2001
    ..6, 95% CI: 1.2-5.8). Increased mortality in type 2 diabetic subjects is therefore attributable to multiple risk factors. Improved outcomes will depend on interventions targeted at glycaemic and all other remediable factors...
  9. ncbi What is the best predictor of the atherogenic LDL subclass phenotype 'pattern B' in patients with type 2 diabetes mellitus?
    R I King
    Clinical Biochemistry, Canterbury Health Laboratories, Christchurch, New Zealand
    Ann Clin Biochem 48:166-9. 2011
    ..We compared the sdLDL assay and LDL-C:Apo-B with more established lipid parameters to predict the presence of 'pattern B' phenotype...
  10. ncbi A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria
    B I Shand
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabetes Nutr Metab 14:201-6. 2001
    ..These changes in vasoactivity have the potential to combine with other cardiovascular risk factors to enhance the development of atheroma...
  11. ncbi Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in Type 2 diabetic patients compared with the Canterbury (New Zealand) general population
    C M Florkowski
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Diabetes Res Clin Pract 43:199-203. 1999
    ..8%). Genetic susceptibility to haemochromatosis is not an important aetiological factor for diabetes, and targeted screening of diabetic patients for haemochromatosis is not indicated...
  12. ncbi Pseudo-hypertriglyceridaemia: a measurement artefact due to glycerol kinase deficiency
    T A Walmsley
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Postgrad Med J 84:552-4. 2008
    ..Demonstration of a point mutation also excludes a contiguous gene deletion syndrome...
  13. ncbi Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice
    R B Gearry
    Department of Medicine, Christchurch School of Medicine and Health Sciences, New Zealand
    Intern Med J 35:580-5. 2005
    ..Assessing thiopurine methyltransferase (TPMT) status has been recommended to reduce the risk of serious toxicity. Measuring red blood cell (RBC) 6-thioguanine nucleotide (6-TGN) concentrations has been recommended for dose adjustment...
  14. ncbi Circulating levels of isoflavones and markers of 5alpha-reductase activity are higher in Japanese compared with New Zealand males: what is the role of circulating steroids in prostate disease?
    J G Lewis
    Steroid and Immunobiochemistry Laboratory, Canterbury Health Laboratories, P O Box 151, Christchurch 8001, New Zealand
    Steroids 70:974-9. 2005
    ..Significantly the positive association between isoflavones levels and 5alpha-steroids is counter-intuitive to isoflavone intake offering prostate protection, unless this is postulated to occur through other mechanisms...
  15. ncbi A population-based study of bone mineral density in women with longstanding type 1 (insulin dependent) diabetes
    H Lunt
    Diabetes Centre, Christchurch Hospital, Christchurch, New Zealand
    Diabetes Res Clin Pract 40:31-8. 1998
    ..In summary, axial BMD values in subjects with long-standing diabetes were similar to those observed in healthy non diabetic populations...
  16. ncbi Three cases of congenital adrenal hypoplasia with novel mutations in the (NROB1) DAX-1 gene
    B Wheeler
    Paediatric Endocrinology, Department of Paediatrics, Christchurch Hospital, Canterbury, New Zealand
    Ann Clin Biochem 45:606-9. 2008
    ..Over 80 different mutations in this gene have been identified. We present three unrelated cases with variable clinical presentations, all with novel mutations in the DAX-1 gene...
  17. ncbi Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?
    R J MacKay
    Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch 8011, New Zealand
    Ann Clin Biochem 45:535-8. 2008
    ..This has important implications for reporting...
  18. ncbi Quartz renal calculi: were we being led up the garden path?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Ann Clin Biochem 44:312-4. 2007
    ..This case highlights the usefulness of XRD in the differentiation of authentic from possibly factitious renal calculi...
  19. ncbi Urinary VMA, dopamine and the likelihood of neuroblastoma: a preferred way of reporting laboratory results?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand
    Ann Clin Biochem 43:300-5. 2006
    ..We therefore evaluated the utility of positive likelihood ratios (LR+) based on data from patients in whom the diagnosis was suspected...
  20. ncbi The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control
    C H Strey
    Lipid and Diabetes Research Group, Hagley Building, Christchurch Hospital, Christchurch, New Zealand
    Diabetologia 47:1838-46. 2004
    ..CONCLUSIONS/INTERPRETATION: The postprandial state does not impair endothelial function in non-diabetic women and does not make pre-existing endothelial dysfunction worse in women with type 2 diabetes, irrespective of glycaemic control...
  21. ncbi Thiopurine methyltransferase activity and azathioprine
    T A Walmsley
    N Z Med J 115:302. 2002
  22. ncbi Autosomal recessive adult-onset hypophosphatasia
    J R Harraway
    Pathology 37:563-5. 2005
  23. ncbi HbA1c or glucose for diabetes diagnosis?
    C M Florkowski
    Ann Clin Biochem 42:408-9. 2005